Prostate cancers are either low-grade, low-risk forms that may be monitored but otherwise untreated, or they’re serious enough to require surgery and radiation. Monitoring can cause patients anxiety.

Francis Medical has obtained $80 million in venture capital funding to support the development of its water vapor ablation therapy for cancers of the prostate, kidneys and bladder. The series C round ...

Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) procedures in Arizona using the Vanquish® Water ...

Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...

Credit: Thinkstock By 5 years, 92% of men recovered pad-free continence, and 87% had preserved erectile function sufficient for penetration. MRI-guided whole-gland transurethral ultrasound ablation ...

AngioDynamics, Inc. ANGO, yesterday, announced the receipt of the FDA’s 510(k) clearance for the NanoKnife System for prostate tissue ablation. The clearance for the NanoKnife System for prostate ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...

The MarketWatch News Department was not involved in the creation of this content. MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing ...